Engineered versions of the human antimicrobial peptide LL-37 designed for improved stability, selectivity, or potency.
LL-37 variants are modified versions of the human cathelicidin antimicrobial peptide LL-37, engineered to improve upon the parent molecule's properties. While native LL-37 is a potent antimicrobial and immunomodulator, it has limitations: susceptibility to proteolytic degradation, potential cytotoxicity at higher concentrations, and complex pro-inflammatory/anti-inflammatory dual activity.
Research groups have developed various modifications: truncated fragments (like IG-19, GF-17), D-amino acid substitutions for protease resistance, cyclized variants for improved stability, and PEGylated forms for extended half-life. Some variants selectively enhance antimicrobial activity while reducing mammalian cell toxicity.
These analogs represent the next generation of antimicrobial peptide therapeutics — an important area given increasing antibiotic resistance. Several pharmaceutical companies are developing LL-37-derived compounds for wound infections, diabetic ulcers, and systemic infections.
Modified LL-37 fragments have shown improved therapeutic indices (better antimicrobial activity with less host cell toxicity). D-amino acid substitutions create protease-resistant variants effective against drug-resistant bacteria. Some variants show enhanced anti-biofilm activity.
Clinical development of LL-37 analogs is in early stages. The parent compound LL-37 has been tested in Phase 1/2 for venous leg ulcers. Engineered variants may offer improved drug-like properties for systemic administration.
📚 Key Reference: PMID: 20053756 (LL-37 analogs), PMID: 25684581 (engineered cathelicidins)
Varies by specific variant. Generally better therapeutic index than parent LL-37. Limited human data for most variants. Consult your provider.
NOT FDA-approved. Research use only. Various analogs in preclinical development.